Skip to content

Douglas

Just another WordPress site

  • About us
    • Our Story
    • Leadership Team
    • Sustainability
    • Douglas Charitable Trust
    • News & Media
  • What we do
    • Douglas CDMO
    • Contract Manufacturing
    • Co-development
    • Operations
    • Commercial
    • Clinical Trials
    • Douglas Innovation
  • Products
    • Consumer Products
    • Prescription Medicines
    • Automation Products
  • Careers
    • Benefits
    • Interns & Graduates
    • Job Vacancies
  • Contact us

Author: Victoria Hayward

Douglas Pharmaceuticals secures US licensing deal to treat high grade cervical dysplasia

Published 27 September 2023
Categorized as Research

Formation of Clinical Advisory Board for Lead Program R-107

Published 17 February 2023
Categorized as Research

Clinicians China licenced to HTDK Pharmaceuticals

Published 3 October 2022
Categorized as Commercial

New Zealand’s largest medical R&D facility opens in West Auckland

Published 15 September 2022
Categorized as Commercial

Recent Posts

  • Douglas Pharmaceuticals named a finalist in the 2025 Manufacturer of the Year Awards
  • Douglas Takes Out Bronze at the 2025 Southern Cross Wayfinder Awards
  • Douglas continues participation in quality management program
  • Douglas selected for FDA’s Quality Management Maturity pilot study
  • R-107 Phase 2 Study Results for Treatment-Resistant Depression Accepted by Leading Scientific Journal, Nature Medicine

Recent Comments

No comments to show.

Archives

  • April 2025
  • March 2025
  • June 2024
  • May 2024
  • December 2023
  • October 2023
  • September 2023
  • August 2023
  • July 2023
  • April 2023
  • February 2023
  • October 2022
  • September 2022
  • June 2021
  • April 2020
  • November 2019
  • May 2019
  • April 2019
  • January 2019
  • December 2018
  • November 2018

Categories

  • Awards
  • Careers
  • Commercial
  • Corporate Responsibility
  • Large Dispensers
  • Manufacturing
  • Quality
  • Research
Douglas
Proudly powered by WordPress.